Bring your portfolio to life with CSL and these ASX healthcare shares

Healthy Heart

I continue to believe that the healthcare sector is a great place to consider long-term buy and hold investments due to a number of favourable industry tailwinds.

With that in mind, here are three top healthcare shares that I think are in the buy zone today and could provide strong returns for investors over the next 10 years:

CSL Limited (ASX: CSL)

CSL is one of the world’s leading biotherapeutics companies. I believe it is a fantastic buy and hold option due to the quality and strength of its CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies and Seqirus is the second biggest influenza vaccines company globally. In FY 2019 the two businesses continued to shine, with CSL Behring reporting an 11% jump in total revenue to US$7,343 million and Seqirus posting a 12% increase in total revenue to US$1,196 million. Due to increasing demand, the quality of its products, and lucrative development pipeline, I expect more of the same in FY 2020 and beyond.

Nanosonics Ltd (ASX: NAN)

Another top buy and hold option in the healthcare sector is Nanosonics. It is a leading infection control specialist which has carved out a leadership position in ultrasound probe disinfection. Whilst this has led to the company’s trophon EPR system growing its footprint materially over the last few years, it is still only scratching at the surface of its global market opportunity. I expect market share gains and strong growth in recurring revenues from the consumables the system requires to drives above-average growth for a number of years to come. This should be supported by the upcoming launch of secret new products targeting unmet needs.

Pro Medicus Limited (ASX: PME)

Pro Medicus is a leading provider of a full range of radiology IT software and services to hospitals, imaging centres, and healthcare groups worldwide. It experienced strong demand for its offering again in FY 2019, leading to it reporting a 91.9% increase in full year profit to $19.1 million. Given the quality of its products and its sizeable market opportunity, I believe Pro Medicus is capable of continuing this strong form for some time to come.

As well as CSL, Nanosonics, and Pro Medicus, these outstanding ASX shares have been tipped as market beaters over the coming years.

Best Stocks to Buy in 2020 NAMED HERE

You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses… and rapidly returning cash to shareholders with its hefty dividend…

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe… poised for years (or even decades) of tremendous growth…

Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!

SimplyCLICK HERE FOR YOUR FREE REPORT!

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Nanosonics Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.